Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be releasing its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Eton Pharmaceuticals to post earnings of $0.12 per share and revenue of $20.5790 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $18.09 on Thursday. Eton Pharmaceuticals has a 1 year low of $11.09 and a 1 year high of $23.00. The firm’s 50 day moving average is $16.26 and its 200-day moving average is $17.26. The firm has a market capitalization of $485.17 million, a price-to-earnings ratio of -72.36 and a beta of 1.19. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $37,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals during the second quarter worth $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth $44,000. New York State Common Retirement Fund bought a new stake in Eton Pharmaceuticals in the second quarter valued at about $115,000. Finally, State of Wyoming lifted its stake in Eton Pharmaceuticals by 50.0% in the fourth quarter. State of Wyoming now owns 8,161 shares of the company’s stock valued at $138,000 after buying an additional 2,721 shares during the period. Institutional investors own 27.86% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, HC Wainwright upped their price target on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.